Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : JMED - Jones Pharma (specialty pharmaceutical mfr) -- Ignore unavailable to you. Want to Upgrade?

To: Mikeh who wrote (220)	6/23/1999 2:28:00 PM
From: wbASSETt	Read Replies (1) \| Respond to of 268

From article...We here at IIOnline also figure Genzyme (NASDAQ:GENZ - news) and Jones Pharma (NASDAQ:JMED - news) may eventually be a buyout candiate. Genzyme is one of the most profitable biotechnology stocks in the U.S. The company expects to earn $1.85 a share this year, and feels confident in growing its bottom line at a 20% clip. Genzyme's key product is Cerezyme for Gaucher's disease, with sales at around $480 million for that product. The company may also be an acquirer thanks to its plump $500 million cash balance. Jones Pharma can also be a possible candidate for the large drug companies looking to beef up their future earnings outlook. The company is involved in endocrine products, critical care products, and a branch of veterinarian products. Jones has seen unprecedented growth in its products it brings to the marketplace. Recently, the company reported a 24% increase in sales, while net income rose 35% to $9.8 million. The company sports a market cap of a $1 billion, and trades for 26 times trailing earnings. wbASSETt